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ABSTRACT
Background: Hyperbaric oxygen (HBO) is used as
part of treatment in a variety of clinical conditions. Its
use in the treatment of ulcerative colitis has been
reported in few clinical reports.
Objective: We report the effect of HBO on refractory
ulcerative colitis exploring one potential mechanism of
action.
Design: A review of records of patients with refractory
ulcerative colitis who received HBO was conducted.
Clinical and histopathological scoring was utilised to
evaluate the response to HBO therapy (HBOT).
Results: All patients manifested clinical improvement by
the 40th cycle of HBOT. The median number of stool
frequency dropped from seven motions/day (range=3–
20) to 1/day (range=0.5–3), which was significant
(z=−4.6, p<0.001). None of the patients manifested
persistent blood passage after HBOT (z=−3.2, p=0.002).
The severity index significantly improved after HBOT (z=
−4.97, p<0.001). Histologically, a significant reduction of
the scores of activity was recorded accompanied by a
significant increase in the proliferating cell nuclear
antigen labelling index of the CD44 cells of the colonic
mucosa (p=0.001).
Conclusions: HBOT is effective in the setting of
refractory ulcerative colitis. The described protocol is
necessary for successful treatment. HBOT stimulates
colonic stem cells to promote healing.
BACKGROUND
Ulcerative colitis (UC) is an inﬂammatory
bowel disease characterised by colonic
mucosal ulcers and a disturbing alteration of
bowel habits.1 The disease is manifested in
the active phase by increased frequency of
bowel motions with or without lower gastro-
intestinal bleeding. These manifestations are
reversed by induction of mucosal healing
and subsiding inﬂammation.2 Genetic
susceptibility,3 alteration of bacterial ﬂora,4
immune dysfunction5 and abnormal cytokine
production6 are implicated factors, among
others,7 in the pathogenesis of UC. The 5-
aminosalicylate acid (5-ASA) class of drugs is
considered ﬁrst line therapy as it induces
remission in the majority of patients with
mild and moderate disease.8 Patients with
severe disease require adjuvant therapeutic
lines involving corticosteroids and immune
modulators.9 Although these medications are
effective in many cases, in other cases, these
lines are not effective.10 Moreover, they
could have signiﬁcant adverse effects particu-
larly after long-term use.11
Hyperbaric oxygen (ie, the use of 100%
oxygen inhalation in a pressurised room) has
been in clinical use as a therapeutic option
for a variety of medical conditions.12–14
Summary box
What is already known about this subject?
▸ Hyperbaric oxygen has been proposed as a
therapy for several diseases.
▸ Hyperbaric oxygen has an anti-inflammatory
effect.
▸ Hyperbaric oxygen might be useful in ulcerative
colitis.
What are the new findings?
▸ Hyperbaric oxygen stimulates colonic stem cells.
▸ Hyperbaric oxygen seems be useful in the treat-
ment of refractory ulcerative colitis.
How might it impact on clinical practice in
the foreseeable future?
▸ This modality is readily available.
▸ It is inexpensive compared to other lines.
▸ It might have an additional benefit by replenish-
ing the general condition of patients.
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Nevertheless, the utility of hyperbaric oxygen therapy
(HBOT) to treat inﬂammatory bowel diseases did not
receive attention until recently and its use in gastrointes-
tinal conditions is not yet well established. Several
experimental studies have been conducted on laboratory
animal models with induced intestinal diseases such as
ischaemia15 and inﬂammation.16 Among others, these
experiments demonstrated the strong potential for the
use of HBO in the treatment of various gastrointestinal
conditions, with promising results.17 Only a few clinical
studies have reported the use of HBOT in the treatment
of UC.18 Stem cell activation was one of the proposed
mechanisms of the action of HBOT.19
OBJECTIVE
This study aims at presenting our clinical experience in
the use of HBO for the treatment of refractory UC,
investigating the status of colonic stem cells to delineate
a possible mechanism of action for HBOT in this clinical
setting.
Study setting
The study was conducted at the Faculty of Medicine,
University of Alexandria, Egypt.
METHODS
In 1994, a woman with unresponsive severe UC was
referred to undergo hyperbaric oxygen sessions to
improve her general condition prior to a scheduled col-
ectomy. After 40 sessions, the patient’s general condition
improved remarkably along with complete remission of
her colonic symptoms, therefore surgery was deferred.
Thereafter, we systematically offered HBO sessions to
patients with refractory UC.
After institutional review board approval (IRB),
records of patients with refractory UC who were referred
for HBOT were retrieved from a prospectively main-
tained cohort. Those with documented pre-therapy and
post-therapy endoscopic and histopathological data were
included in this study.
Between 1994 and 2011, 32 consecutive patients with
refractory UC were treated with HBOT. We considered
UC refractory when there was minimal or no response
after 4–6 weeks of continuous standard medical therapy.
Besides the dietary management based on a well-
balanced plan, rich in protein, complex carbohydrates,
whole grains and fats, our standard medical therapy was
composed of an escalating regime of 3.2–4.8 g oral
5-ASA/day with a 4 g (5-ASA) enema/day. In more
severe cases, 40–50 mg of oral methylprednisolone were
given daily and tapered over 4–6 weeks along with
2–2.5 mg/kg/day of oral azathioprine. Patients with clin-
ically more severe disease were given intravenous corti-
costeroids (60 mg prednisolone/day). Patients were
judged to have refractory disease when no more than
minimal clinical improvement, based on the Mayo Clinic
Disease Severity Index, manifested after 4–6 weeks of
maximal dose therapy.20
HBOT was performed in two multiplaced hyperbaric
chambers. The ﬁrst chamber was a Sebi—a Gorman
design built in England in 1973, with a 200 cm diameter
—which was used until 2003. Thereafter, a second
chamber, a Haux Starmed 2000—built in Germany in
2002, with a 200 cm diameter—was used. Patients were
subjected to gradual compression and decompression at
2–3 psi/min (pounds per square inch) with air at the
beginning and end of each session.
The total oxygen breathing time was 60 min with a
5 min air break at 30 min. The hyperbaric cycles were
given at a pressure depth of 2.8 atmospheric absolute
(ATA) (equivalent to 18 m). The sessions were repeated
ﬁve times per week for eight consecutive weeks. All
patients received their medical therapy contemporan-
eously with the hyperbaric sessions.
From 1 to 3 weeks after completion of the hyperbaric
sessions, a follow-up colonoscopy was performed and
multiple punch biopsies were taken from different areas
during the examination. The majority of colonoscopic
examinations were performed after colon preparation.
Endoscopic grading was assigned following scores
described in the Mayo Clinic Grading Scale.20 We did
not keep data on the severity of blood passage per anus,
hence we only had information on the presence or
absence of blood passage. Therefore we calculated the
severity score index using 9 instead of 12 levels.
All endoscopic examinations were performed by a
single consultant (YT) and the cohort data maintained
by the senior author (EM).
Morphometric analysis
All morphological evaluations were performed by one of
the authors (NB) blinded to the patients’ codes. At least
18 serial sections of every biopsy were examined and
histopathological scores of activity given according to
the adopted scoring system from Geboes.21 Scores were
assigned to the different categories according to the
worst area in the examined biopsy. A standard point-
counting method22 was used to quantitate CD44 positiv-
ity, using Steptovidin–perioxidase (ab64269, Abcam,
USA), to estimate the number of stem cells in the
mucosa. Towards that end, 12 consecutive non-
overlapping ﬁelds were evaluated in quantiﬁcation of
CD44 positivity, using an Olympus microscope (CH 20
BIMF 200, Olympus, China) under a magniﬁcation of
×400. A total of 81×12 points (number of intersections
in the grid used) were evaluated in each biopsy. All glan-
dular proﬁles in the biopsy were point counted. All posi-
tively stained points falling on the grid’s cross-points
were counted. Negatively stained glandular epithelial
cells falling on the intersections of the counting grid
were also counted.
The mean score per biopsy was calculated. The results
are expressed as the percentage of positively stained
points of the total number of points counted.
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The proliferating cell nuclear antigen labelling index
(PCNA/LI) was counted as a percentage of nuclei
counted in a ﬁeld of 0.15 mm of an ×400 magniﬁcation,
using the following formula: number of positively stain-
ing nuclei/number of positively stained nuclei and
number of negatively stained nuclei.22
During evaluation of the biopsy, only positively stained
glandular epithelial cells with deeply stained nuclei were
counted as positive. Fields with positively stained inﬂam-
matory cells, smooth muscle ﬁbres or ﬁbroblasts, were
ignored.
Statistical analysis
The continuous data are expressed in mean±SD, and
median and range, according to the normality of distribu-
tion test. The signiﬁcance of differences between the clin-
ical groups (before and after treatment) was determined
by Wilcoxon signed rank test, and used for non-parametric
paired data. Correlations between the different parameters
were performed using the Spearman’s rank correlation
test. A p value of <5% was considered signiﬁcant. All ana-
lysis was performed using the statistical software package
SPSS V.20 (IBM Inc, Chicago, Illinois, USA).
RESULTS
The median age of the included patients was 34.5 years
(range 19–50). Fifty per cent of the patients were
females. All the patients (100%) included in the present
study who underwent HBOT therapy for refractory UC
demonstrated a remarkably favourable clinical improve-
ment as well as improvement in both, the endoscopic
and histopathologic parameters used for assessment of
the response to therapy.
Clinical evaluation
All patients manifested clinical improvement by the 40th
cycle of HBOT. The median number of stool frequency
in the pre-HBOT stage was 7 motions/day (range=3–20),
which was signiﬁcantly (z=−4.6, p<0.001) decreased to a
median of 1 motion/day (range=0.5–3). None of the
patients manifested persistent blood passage after the
HBOT (z=−3.2, p=0.002).
Endoscopic evaluation and activity scoring
Endoscopic evaluation demonstrated a highly signiﬁcant
reduction of disease activity scores (z=−5.156, p<0.001).
The pre-HBOT scores were (median=2, range=1–3) as
compared with the post-HBOT scores (median=0,
range=0–1) (ﬁgures 1–3). Table 1 summarises the
patients’ disease severity scoring.
The median disease severity index was 7 (range=5–9)
in the pre-HBOT assessment sheets, which was signiﬁ-
cantly decreased to a median of 0 (range=0–3) after the
HBOT (z=−4.97, p<0.001).
Histopathological evaluation
Histologically, a signiﬁcant reduction in the scores of
activity was recorded and is summarised in table 2.
The chronic inﬂammatory inﬁltrate in the lamina
propria (ﬁgure 4), the numbers of neutrophils inﬁltrat-
ing the lamina propria (ﬁgure 5) and the surface epi-
thelium (ﬁgure 6), crypt destruction and surface
erosions/ulcerations (ﬁgure 7), were observed. Signs of
Figure 1 Endoscopic picture of
ulcerative colitis with (A) Mayo
grade 2 score with significant
oedema, absent vessel markings
and small ulcers, (B) Mayo grade
0 score of the same patient
showing inactivity of the disease
post-treatment colonoscopy.
Figure 2 Endoscopic picture of
ulcerative colitis with (A) Mayo
grade 3 score with significant
oedema, absent vessel markings
and spontaneously bleeding
ulcers, (B) Mayo grade 1 score of
the same patient showing
significant reduction of the activity
of the disease post-treatment
colonoscopy.
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chronicity as architectural distortion did not exhibit sig-
niﬁcant improvement (p>0.05).
Other signs of healing observed in the post-treatment
biopsies included a signiﬁcant increase in the degree of
ﬁbrosis of the lamina propria (ﬁgure 8), as well as res-
toration of the goblet cell component of the glands
(ﬁgure 9).
Immunohsitochemical determination of the numbers of
CD44 positive stem cells in the colonic biopsies
PCNA labelled the nuclei of the epithelial cells and
inﬂammatory cells as well as the ﬁbroblasts. A signiﬁcant
increase (p=0.001) in the PCNA/LI was observed in the
post-treatment biopsies as compared with the pre-
treatment biopsies (x=20.56+1.88, range=18–26 vs
x=16.03+1.09, range=14–18, respectively) (ﬁgures 10
and 11).
CD44 positivity was observed in the membranes of the
glandular epithelium. A signiﬁcant increase (p=0.001)
was observed between pretreatment and post-treatment
biopsies; (x=6.56+0.5, range=6–7) in the pre-treatment
(x=9.13+0.61, range=8–12) versus in the post-treatment
biopsies (ﬁgure 12). This increase was accompanied by a
signiﬁcant increase in the PCNA/LI (p=0.001).
In the post-treatment biopsies, a signiﬁcant correlation
was detected between the PCNA/LI and CD44 positivity
(r=0.86, p=0.001). Also, a signiﬁcant correlation was
seen between the scores of the erosions and the PCNA/
LI (r=6.82, p=0.008) as well as, in an inverse pattern,
between the scores of inﬂammation and CD44 positivity
(r=−0.813, p=0.001).
DISCUSSION
Our series is one of the largest reported in the English
literature, with documented mucosal healing in cases of
UC treated with HBOT. In this study, the use of hyper-
baric oxygen in the treatment of refractory UC proved
to be effective. This adds to the accumulating evidence
on the efﬁcacy of HBOT in the treatment of UC.18
Figure 3 Endoscopic picture of
ulcerative colitis with (A) Mayo
grade 3 score with friable mucosa
and large ulcers. (B) Mayo grade
0 score of the same patient
showing inactive disease
post-treatment colonoscopy.
Table 1 Summary of patients’ disease severity index
according to the Mayo Clinic20
Pre-HBOT Post-HBOT p Value*
Stool frequency
(median/range)
7 (3–20) 1 (0.5–3) <0.001
Blood passage
(number of patients)
10 0 0.002
Endoscopy
Grade 0 0 25 <0.001†
Grade I 2 7
Grade II 20 0
Grade III 10 0
Severity score
index‡ (median/
range)
7 (5–9) 0 (0–3) <0.001
*p Value driven from the Wilcoxon singed ranks test.
†p Value is calculated using the same test for the central
tendency and dispersion of all grades, not only grade 0.
‡Scoring was calculated using 9 instead of 12 levels, due to the
absence of detailed data about severity of passage of blood per
anus, which was excluded from the nominator.
HBOT, hyperbaric oxygen therapy.
Table 2 Histopathological changes of the mucosa
induced by hyperbaric oxygen therapy in patients with
refractory ulcerative colitis
Pathological
feature
Median*
(range)
Pre-therapy
Median
(range)
Post-therapy p Value†
Architectural
changes
0.3 (0.2–0.3) 0.3 (0.2–0.3) >0.05
Chronic
inflammation
1.3 (1.2–1.3) 1.1 (1–1.1) <0.001
Eosinophils in
the lamina
propria
2.15 (2–2.5) 2.05 (2–2.2) <0.001
Neutrophils in
the lamina
propria
2.1 (2.0–2.1) 2.0 (2.0–2.0) <0.001
Neutrophils in
the epithelium
3.3 (3.1–3.3) 3.1 (3.1–3.2) <0.001
Crypt
destruction
4.3 (4.1–4.3) 4.1 (4–4.1) <0.001
Surface
erosions/
ulcerations
5.3 (5.2–5.3) 5.1 (5.0–5.1) <0.001
*The median was used to express the central tendency instead of
the mean rank, to facilitate interpretation by the reader.
†p Value is estimated from Wilcoxon signed rank test.
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Moreover, it promotes mucosal healing, which is a
primary target for all therapeutic regimens of UC.2
One of the recognised intermediate mechanisms in
UC is mucosal hypoxia.23 This could be supported by
the presence of reduced rectal blood supply in some
affected individuals.24 Mucosal hypoxia increases the oxi-
dative stress factors that lead to reduction of mitochon-
drial functions25 with further expression of
inﬂammatory factors,26 which, in turn, reduces oxygen-
ation through increased oedema formation. Hyperbaric
oxygen is suggested to exert its effect through reducing
the inﬂammation and promoting mucosal healing.27 28
It induces down regulation of the hypoxia-induced
inﬂammation.29
One of the proposed mechanisms of action of HBOT
is promoting mucosal healing by increasing the
numbers of stem cells in the colonic mucosa. It pro-
motes the differentiation of colonic stem cells, resident
in the colonic mucosal crypts, and migration of bone
marrow stem cells to the colonic mucosa,30 to aid in the
repair process.
CD44 has been found to be a marker of stem cells
activity in several organs, including the colon.31 32 In the
present study, CD44 was found to be increased in post-
treatment biopsies and to correlate with mucosal glandu-
lar epithelial cell proliferation and mucosal healing.
Ditschkowski et al33 reported the clinical improvement
of UC symptoms following allogeneic stem cell trans-
plant, which is supported by our ﬁndings. The inﬂuence
of HBOT along with stem cell transplant is reported to
be more profound than stem cell transplant alone, in an
experimental study.34 In our study, it appears that the
stimulation of stem cell activity plays an important role
in the remission of disease activity. This is in line with
the reported sentinel role of stem cells as an anti-
inﬂammatory guardian,35 which was found to down
regulate inﬂammation.36
The observed increase in the ﬁbrosis score in post-
treatment biopsies in the present study is another mech-
anism of action of HBOT. HBOT is reported to stimulate
the proliferation of ﬁbroblasts in a dose-dependent
fashion.37 The deposition of ﬁbroblasts in the different
Figure 4 Pre (A) and post (B)
biopsies showing marked
reduction of the intensity of the
inflammatory infiltrate in the
mucosa (H&E, ×200).
Figure 5 Pre (A) and post (B)
treatment biopsies showing
marked reduction in the numbers
of neutrophils in the lamina
propria and crypt epithelium
(H&E, ×400).
Figure 6 Pre (A) and post (B)
treatment biopsies showing
marked reduction in the numbers
of neutrophils in the surface
epithelium (H&E, ×400).
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subepithelial layers could explain the insigniﬁcant
change of the architecture despite the signiﬁcant
improvement of all parameters of the utilised histo-
pathological scoring system.
On the other hand, there are reports of potential
complications of HBOT. Simsek et al,38 in an experimen-
tal study, reported that repeated exposure to hyperbaric
oxygen could lead to accumulation of oxidative stress in
the lung tissue. A few complications have also been
reported in clinical settings following hyperbaric therapy
for clinical conditions other than UC.39 40
There were no adverse effects inﬂicted by HBOT fol-
lowing our therapeutic protocol. A low complication
rate was reported in different clinical reports of UC
treated with hyperbaric oxygen,41 42 and for other clin-
ical conditions.43 Moreover, when compared with other
Figure 8 Pre- (A) and post- (B)
treatment biopsies showing an
increase in the degree of fibrosis
of the lamina propria in the
post-treatment biopsy (Masson
Trichrome, ×100).
Figure 9 Pre (A) and post (B)
treatment biopsies showing
restoration of the goblet cell
component of the epithelium
(H&E, ×200).
Figure 7 Pre (A) and post (B)
treatment biopsies showing
significant mucosal healing (H&E
stain, ×200).
Figure 10 A section of a
pre-treatment colonic biopsy in
the active stage (A) showing a
well developed crypt abscess.
<(B)> Note the PCNA/LI (PCNA,
streptavidin peroxidase, (A) ×200,
(B) ×400).
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therapeutic lines for the treatment of refractory UC, no
studies reporting on the clinical use of HBOT for UC
reported any signiﬁcant complications.18
There was no uniﬁed therapeutic protocol in the pub-
lished literature for the use HBOT in UC.44 45 Buchman
et al46 reported successful therapy in a single case at a
pressure of 2 ATA. In our patients, we noticed that a
pressure of 2.8 ATA was important for the therapy to be
effective.
In the present study, we used two chambers for treat-
ment delivery, as reported in the ‘Methods’ section of
this paper. Treatment sessions at the older chamber
(Sebi Gorman, 1973) were delivered at 2.8 ATA. At the
beginning of the use of the newer chamber (Haux
Starmed, 2000), treatments were delivered at a pressure
of 2.5 ATA (equivalent to 15 m). Treatments given at this
pressure were not as clinically successful as expected. On
modifying treatment pressures to 2.8 ATA, the treated
patients demonstrated signiﬁcant improvement. Four
patients were treated ﬁrst with 2.5 ATA pressure protocol
and were not included in this study, to avoid the possible
inﬂuence of a synergistic dose effect. The heterogeneity
of the reported therapeutic protocols could be attribu-
ted to the limited number of published cases, the vari-
ation in the deﬁnition of refractoriness and the severity
of disease in each series as well as the different patient
demographics.41 44 46
Reduction in the cost of care has been demonstrated
for other diseases treated with HBO.47 Although the
same concept applies for refractory UC, no sufﬁcient
data are currently available to support this information
for UC therapy. Nonetheless, it would be much cheaper
when compared to relatively new therapeutic lines such
as inﬂiximab. Recent reports demonstrated the efﬁcacy
of inﬂiximab in refractory UC.48 None of the patients in
this report received this treatment.
The major caveat of this study is the non-controlled
design. Nonetheless, our results are encouraging for
future randomised controlled studies to be conducted to
provide stronger evidence on the true value of hyperbaric
oxygen in the treatment of refractory and even non-
refractory UC, and to further explore the possible thera-
peutic mechanisms of HBO in the treatment of UC.
CONCLUSION
HBOT is effective in the setting of refractory UC. The
described protocol is necessary for successful treatment.
The mechanism of action of HBOT in treatment of
refractory cases of UC involves stimulation of colonic
stem cells to promote healing.
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Figure 12 Pre and
post-treatment biopsies showing
an increase in CD44
membranous staining (CD44
monoclonal antibody, streptavidin
peroxidase technique, ×200).
Figure 11 Section of a
post-treatment colonic biopsy
showing a high PCNA/LI (PCNA,
streptavidin peroxidase, (A) ×200,
(B) ×400).
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